UIH(SH:688271)2024-04-26 13:47Financial Performance - The company's operating revenue for Q1 2024 was ¥2,350,478,362.11, representing a year-on-year increase of 6.22%[4] - The net profit attributable to shareholders was ¥363,297,720.56, reflecting a growth of 10.20% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥300,194,937.03, an increase of 8.52% year-on-year[4] - Total operating revenue for Q1 2024 reached ¥2,350,478,362.11, an increase of 6.25% compared to ¥2,212,870,463.39 in Q1 2023[19] - Net profit for Q1 2024 was ¥361,942,371.76, compared to ¥325,526,611.76 in Q1 2023, representing a growth of 11.16%[21] - Total comprehensive income for Q1 2024 reached ¥362,987,690.02, an increase from ¥320,718,943.78 in Q1 2023, representing a growth of approximately 13.2%[22] - Basic and diluted earnings per share for Q1 2024 were both ¥0.44, up from ¥0.40 in Q1 2023, indicating a 10% increase[22] Research and Development - Research and development expenses totaled ¥506,949,927.30, accounting for 21.57% of operating revenue, which is an increase of 2.12 percentage points[6] - Research and development expenses for Q1 2024 amounted to ¥419,681,857.09, slightly increasing from ¥412,457,903.29 in Q1 2023[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥25,347,749,297.37, a slight increase of 0.05% from the end of the previous year[6] - The company's current assets totaled RMB 19,770,733,478.26, down from RMB 20,227,806,280.02 in the previous period[16] - The total liabilities decreased to ¥6,079,087,771.00 in Q1 2024 from ¥6,454,724,356.28 in Q1 2023, a reduction of approximately 5.80%[18] - The total equity attributable to shareholders increased to ¥19,225,030,179.95 in Q1 2024 from ¥18,866,353,649.67 in Q1 2023, marking an increase of 1.90%[18] - The total non-current assets reached RMB 5,577,015,819.11, up from RMB 5,108,334,041.94[16] Cash Flow - The net cash flow from operating activities was -¥657,050,656.93, attributed to a decrease in sales receipts[4][8] - Cash inflow from operating activities totaled ¥2,077,775,422.40, down from ¥2,610,056,376.38 in the previous year, reflecting a decrease of about 20.4%[23] - Net cash outflow from operating activities was ¥657,050,656.93, compared to a net outflow of ¥313,565,330.56 in Q1 2023, indicating a worsening cash flow situation[23] - Cash inflow from investment activities amounted to ¥3,218,668,313.04, significantly higher than ¥2,011,147,671.24 in Q1 2023, marking an increase of approximately 60%[24] - Net cash outflow from investment activities was ¥1,123,792,938.39, an improvement from the outflow of ¥1,470,765,954.23 in the same period last year[24] - Cash inflow from financing activities was ¥7,800,000.00, up from ¥4,200,000.00 in Q1 2023, showing an increase of 85.7%[24] - The net cash outflow from financing activities was ¥52,965,585.80, compared to an outflow of ¥10,893,128.25 in Q1 2023, indicating a larger cash drain[24] - The ending balance of cash and cash equivalents was ¥5,695,446,410.92, down from ¥7,826,631,778.09 at the end of Q1 2023, a decrease of approximately 27.2%[24] Shareholder Information - The top shareholder, 联影医疗技术集团有限公司, holds 20.33% of the shares, totaling 167,550,968 shares[10] - The company reported a total of 16,859 common shareholders at the end of the reporting period[10] - The company has not reported any significant changes in its shareholder structure or related party transactions during the reporting period[12] Other Information - The company received government subsidies amounting to ¥45,913,640.25, which are closely related to its normal business operations[7] - There are no other important reminders regarding the company's operational situation during the reporting period[14] - The company did not apply new accounting standards for the first quarter of 2024[25]